modelA02AC01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | CalciumCarbonate | |
| ATC code: | A02AC01 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0.02 | L/kg/h |
| other parameters in model implementation | ||
Calcium carbonate is an inorganic compound commonly used as a dietary calcium supplement or antacid. It is approved for use in the treatment and prevention of calcium deficiency, osteoporosis, and as an adjunct therapy for conditions that benefit from increased calcium intake. It is widely available over the counter and is considered safe when used as directed.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult individuals from secondary sources; limited clinical PK studies due to its poor systemic absorption.
References
Junkert, AM, et al., & Pontarolo, R (2024). Pharmacokinetics of oral ciprofloxacin in adult patients: A scoping review. British journal of clinical pharmacology 90(2) 528–547. DOI:10.1111/bcp.15933 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37850318
Wiria, M, et al., & Pouteau, E (2020). Relative bioavailability and pharmacokinetic comparison of calcium glucoheptonate with calcium carbonate. Pharmacology research & perspectives 8(2) e00589–None. DOI:10.1002/prp2.589 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32302064
Pai, MP, et al., & Amsden, GW (2006). Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 5(3) 153–157. DOI:10.1016/j.jcf.2006.01.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16481224
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)